Use of insulin glargine in children under age 6 with type 1 diabetes

Dixon, Brenner; Chase, H. Peter; Burdick, Jonathan; Fiallo‐Scharer, Rosanna; Walravens, P.; Klingensmith, Georgeanna J.; Rewers, Marian; Garg, Satish K.

doi:10.1111/j.1399-543x.2005.00115.x

Cited by 48 publications

(56 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As supported by previous studies in adolescents and children [10,12,18,19] we also observed a significant drop in the incidence of overall and symptomatic and severe symptomatic hypoglycemia in the insulin glargine group. As per the EURODIAB ACE study group [20], the most rapid rate of increase of T1D in children is in those under age 5 and symptomatic hypoglycemia occurred in 55% of 0-2 years, 45% 0f 2-5 years and 13% of >5 years of age [21], hence this group could benefit most from glargine therapy.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Comparative Efficacy of Once Daily Insulin Glargine with Twice Daily NPH Insulin in Children with Type 1 Diabetes

Saini¹,

Devidayal²,

Verma³

et al. 2011

J Diabetes Metab

View full text Add to dashboard Cite

Objective: To compare the efficacy of insulin glargine and insulin NPH in terms of glycemic control and risk of hypoglycemia in children with Type 1 diabetes (T1D) mellitus.Design: Prospective, randomized, open label, controlled trial.Setting: Pediatric Diabetes Clinic of a tertiary care hospital.Subjects: Eighty T1D children between 2 to12 years diagnosed for at least six months. Randomization:Computer generated random number table was used to randomize the patients into Glargine (n=40) and NPH (n=40) groups. Intervention:Patients received either once daily insulin glargine or twice daily NPH insulin as basal insulin. Monthly follow up was done for 6 consecutive months. Results:In the glargine group, significant reductions were noted from baseline to endpoint in mean fasting blood glucose (FBG) (152.80 ± 22.92 versus 113.08 ± 14.71, p value < 0.001), mean blood glucose (MBG) (171.0 ± 23.02 versus 126.20 ± 13.29, p value < 0.001), glycated hemoglobin (HbA1c) (8.89 ± 1.48 versus 7.44 ± 0.74, p value < 0.001), mean total insulin dose (0.92 ± 0.37 units/kg/day versus 0.70 ± 0.29, p value < 0.043), mean basal insulin dose (0.78 ± 0.34 versus 0.53 ± 0.23, p value < 0.001) and mean number of all types of hypoglycemic episodes whereas, mean unmodified insulin dose (0.14 ± 0.14 versus 0.16 ± 0.14, p value 1.000) remained unchanged. The changes in all these parameters in the NPH group were not significant. The percentage of patients suffering at least one episode of hypoglycemia was significantly less with glargine in contrast to NPH (2.02 ± 0.43 versus 2.36 ± 0.47, p value 0.001). Conclusion:Glargine was found to be more effective than NPH insulin for glycemic control and incidence of hypoglycemia in children with T1D.

show abstract

Section: Discussionsupporting

confidence: 90%

“…While the mean total and the basal insulin doses decreased significantly, the mean unmodified insulin dose increased non-significantly in the glargine group as compared to NPH group. Comparable results have been shown earlier [15,22] though higher insulin requirement with glargine has also been reported in literature [12,19].…”

Section: Discussionsupporting

confidence: 85%

Comparative Efficacy of Once Daily Insulin Glargine with Twice Daily NPH Insulin in Children with Type 1 Diabetes

Saini¹,

Devidayal²,

Verma³

et al. 2011

J Diabetes Metab

View full text Add to dashboard Cite

show abstract

“…Dixon et al (2005) 79 recruited children under 6 years of age, whereas Murphy et al (2003) 86 studied adolescents, and Schober et al (2002) 90 included children and adolescents. The other studies were in adults.…”

Section: The Comparatormentioning

confidence: 99%

Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation

Cummins

Royle²,

Snaith³

et al. 2010

Health Technol Assess

184

155

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of project...

show abstract

“…Insulin glargine is not currently approved for pediatric patients under the age of 6 years, although observational studies to date demonstrate short-term safety and effectiveness in this age group. Dixon et al [26] conducted a retrospective electronic medical record chart review of 64 children under the age of 6 years who were initiating insulin glargine and compared them to a control group matched for age, gender, and diabetes duration. The group of children initiating insulin glargine had a dramatic reduction in severe hypoglycemia, particularly at night.…”

Section: Insulinmentioning

confidence: 99%

Technology and intensive management in youth with type 1 diabetes: State of the art

Wood

Laffel

2007

Curr Diab Rep

View full text Add to dashboard Cite

Recent implementation of technologic advances in the management of pediatric type 1 diabetes creates an exciting time for the diabetes community. Safety and efficacy of new therapies are commonly demonstrated first in adult patients with pediatric studies following. This review covers recent advances in six main areas: blood glucose monitoring including continuous monitoring; point-of-care A1c testing; designer insulins; insulin delivery systems including insulin pumps; electronic communication; and telehealth.

show abstract

Use of insulin glargine in children under age 6 with type 1 diabetes

Abstract: SH was decreased, particularly at night (from 12 episodes to one), after the introduction of glargine in young children with T1D.

Cited by 48 publications

References 22 publications

Comparative Efficacy of Once Daily Insulin Glargine with Twice Daily NPH Insulin in Children with Type 1 Diabetes

Comparative Efficacy of Once Daily Insulin Glargine with Twice Daily NPH Insulin in Children with Type 1 Diabetes

Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation

Technology and intensive management in youth with type 1 diabetes: State of the art

Contact Info

Product

Resources

About